Liposomal delivery of hydrophobic weak acids: Enhancement of drug retention using a high intraliposomal pH

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 433-454

  Joguparthi, Vijay ^a   Anderson, Bradley D ^a  

^a University of Kentucky   (United States)

Author keywords

Cancer chemotherapy; Controlled delivery; Controlled release; Formulation; Liposomes; Mathematical model; Nanoparticles; Passive diffusion transport; Permeability; Phospholipids

Indexed keywords

CAMPTOTHECIN; DB 67; UNCLASSIFIED DRUG;

ARTICLE; DRUG RELEASE; DRUG RETENTION; IN VIVO STUDY; KINETICS; LIPOSOMAL DELIVERY; MEMBRANE BINDING; MEMBRANE PERMEABILITY; PH;

EID: 38349106839     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21135     Document Type: Article

References (57)

1. Gabizon AA. 2001. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7:223-225.
2. Gabizon AA. 2002. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 10:535-538.
3. Gabizon A. 2003. Emerging role of liposomal drug carrier systems in cancer chemotherapy. J Liposome Res 13:17-20.
4. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436.
5. Gabizon AA. 2001. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424-436.
6. Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. 1995. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1239:145-156.
7. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. 2004. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96: 449-461.
8. Abraham SA, Edwards K, Karlsson G, MacIntosh S, Mayer LD, McKenzie C, Bally MB. 2002. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565:41-54.
9. Cheung BC, Sun TH, Leenhouts JM, Cullis PR. 1998. Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta 1414:205-216.
10. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. 2005. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release 104:271-288.
11. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. 2004. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661:47-60.
12. Fenske DB, Wong KF, Maurer E, Maurer N, Leenhouts JM, Boman N, Amankwa L, Cullis PR. 1998. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1414:188-204.
13. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Suss R. 2006. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta 1758:1633-1640.
14. Haran G, Cohen R, Bar LK, Barenholz Y. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201-215.
15. Liu X, Lynn BC, Zhang J, Song L, Bom D, Du W, Curran DP, Burke TG. 2002. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc 124:7650-7651.
16. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. 1990. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53:37-46.
17. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. 1999. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta 1416: 1-10.
18. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally M. 2006. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res 23:2799-2808.
19. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. 2006. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release 114:78-88.
20. Zhigaltsev TV, Maurer N, Akhong QF, Leone R, Leng E, Wang J, Semple SC, Cullis PR. 2005. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 104:103-111.
21. Zhigaltsev IV, Maurer N, Edwards K, Karlsson G, Cullis PR. 2006. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release 110: 378-386.
22. Garcia-Carbonero R, Supko JG. 2002. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661.
23. Pizzolato JF, Saltz LB. 2003. The camptothecins. Lancet 361:2235-2242.
24. Ulukan H, Swaan PW. 2002. Camptothecins: a review of their chemotherapeutic potential. Drugs 62:2039-2057.
25. Zunino F, Pratesi G. 2004. Camptothecins in clinical development. Expert Opin Investig Drugs 13:269-284.
26. Fassberg J, Stella VJ. 1992. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684.
27. Burke TG, Mi Z. 1993. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285-287.
28. Burke TG, Mi Z. 1994. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40-46.
29. Mi Z, Burke TG. 1994. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336.
30. Mi Z, Burke TG. 1994. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33:12540-12545.
31. Burke TG, Mishra AK, Wani MC, Wall ME. 1993. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352-5364.
32. Bom D, Curran DP, Chavan AJ, Kruszewski S, Zimmer SG, Fraley KA, Burke TG. 1999. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 42:3018-3022.
33. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG. 2000. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970-3980.
34. Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. 2001. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48: 83-87.
35. Pratesi G, Beretta GL, Zunino F. 2004. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15:545-552.
36. Iyer L, Ratain MJ. 1998. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42 S31-S43.
37. Scott DO, Bindra DS, Stella VJ. 1993. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 10:1451-1457.
38. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. 2004. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10:6638-6649.
39. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. 2000. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60:3389-3393.
40. Xiang TX, Anderson BD. 2002. Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin. Pharm Res 19:1215-1222.
41. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. 2004. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270:93-107.
42. Emerson DL, Bendele R, Brown E, Chiang S, Desjardins JP, Dihel LC, Gill SC, Hamilton M, LeRay JD, Moon-McDermott L, Moynihan K, Richardson FC, Tomkinson B, Luzzio MJ, Baccanari D. 2000. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 6:2903-2912.
43. Pal A, Khan S, Wang YF, Kamath N, Sarkar AK, Ahmad A, Sheikh S, Ali S, Carbonaro D, Zhang A, Ahmad I. 2005. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 25: 331-341.
44. Zamboni WC, Jung LL, Strychor S, Joseph E, Fetterman SA, Burke TG, Curran DP, Egorin MJ, Eiseman JL. Unpublished results.
45. Joguparthi V, Xiang TX, Anderson BD. 2006. Liposome Transport of Hydrophobic Drugs: Gel Phase Lipid Bilayer Permeability and Partitioning of the Lactone Form of a Hydrophobic Camptothecin, DB-67. J Pharm Sci (in press).
46. Laiken ND, Fanestil DD. 1989. Body Fluids and Renal Function: Physiology of body fluids. In: West JB, editor. Best and Taylor's physiological basis of medical practice, 12th edition. Baltimore: William & Wilkins Publishing Co. pp 406-418.
47. Mayer PT, Xiang TX, Anderson BD. 2000. Independence of substituent contributions to the transport of small molecule permeants in lipid bilayers. AAPS Pharm Sci 2:E14.
48. Xiang T, Xu Y, Anderson BD. 1998. The barrier domain for solute permeation varies with lipid bilayer phase structure. J Membr Biol 165: 77-90.
49. Feil MM. 1995. Lipid phase structure contributions to the bilayer barrier function. Ph.D. Dissertation. University of Utah.
50. Joguparthi V, Feng S, Anderson BD. 2006. Unpublished results.
51. Gutknecht J, Bisson MA, Tosteson FC. 1977. Diffusion of carbon dioxide through lipid bilayer membranes: effects of carbonic anhydrase, bicarbonate, and unstirred layers. J Gen Physiol 69:779-794.
52. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. 2006. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66: 3271-3277.
53. Mayer LD, Reamer J, Bally MB. 1999. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88:96-102.
54. Erdei L, Csorba I, Thuyen HX. 1975. Simple, rapid method for detecting phase transititons of lipids. Lipids 10:115-117.
55. Xiang TX, Anderson BD. 1994. Substituent contributions to the transport of substituted p-toluic acids across lipid bilayer membranes. J Pharm Sci 83:1511-1518.
56. Xiang TX, Anderson BD. 1997. Permeability of acetic acid across gel and liquid-crystalline lipid bilayers conforms to free-surface-area theory. Biophys J 72:223-237.
57. Xiang TX, Anderson BD. 1998. Phase structures of binary lipid bilayers as revealed by permeability of small molecules. Biochim Biophys Acta 1370: 64-76.